Kronos Bio Terminates Cambridge Lease Agreement

Kronos Bio ( (KRON) ) just unveiled an announcement.

On June 4, 2025, Kronos Bio, Inc. entered into a Lease Termination Agreement with BMR-Rogers Street LLC to terminate their office and laboratory lease in Cambridge, Massachusetts, effective June 30, 2025. This termination, which involved a payment of $22.5 million and a return of a $2 million security deposit, is expected to result in approximately $18.2 million in cost savings for the company.

The most recent analyst rating on (KRON) stock is a Buy with a $2.25 price target. To see the full list of analyst forecasts on Kronos Bio stock, see the KRON Stock Forecast page.

Spark’s Take on KRON Stock

According to Spark, TipRanks’ AI Analyst, KRON is a Neutral.

Kronos Bio faces significant challenges with ongoing unprofitability and a weak valuation. Financial performance is hindered by high operational costs and declining equity. Technical indicators suggest a bearish trend, further impacting the stock’s outlook. However, recent corporate events, including a merger and lease termination, provide some positive strategic direction, slightly mitigating the overall negative sentiment.

To see Spark’s full report on KRON stock, click here.

More about Kronos Bio

Kronos Bio, Inc. operates in the biotechnology industry, focusing on the development of novel cancer therapeutics.

Average Trading Volume: 538,597

Technical Sentiment Signal: Sell

Current Market Cap: $41.46M

Learn more about KRON stock on TipRanks’ Stock Analysis page.